AR070573A1 - Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento - Google Patents
Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamentoInfo
- Publication number
- AR070573A1 AR070573A1 ARP090100392A ARP090100392A AR070573A1 AR 070573 A1 AR070573 A1 AR 070573A1 AR P090100392 A ARP090100392 A AR P090100392A AR P090100392 A ARP090100392 A AR P090100392A AR 070573 A1 AR070573 A1 AR 070573A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- representing
- alkoxy
- atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940126601 medicinal product Drugs 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000002825 nitriles Chemical class 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 101150056450 UTS2R gene Proteins 0.000 abstract 1
- 102100020942 Urotensin-2 receptor Human genes 0.000 abstract 1
- 208000035868 Vascular inflammations Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000002560 nitrile group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006169 tetracyclic group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los compuestos tienen la aplicacion en terapéutica como antagonistas de los receptores de urotensina 2 para el tratamiento de la insuficiencia cardiaca, infarto de miocardio, enfermedades coronarias, hipertension, insuficiencia renal, diabetes inflamacion vascular y enfermedades neurodegenerativas. Reivindicacion 1: Compuesto que responde a la formula (1) en la que: X e Y representan independientemente el uno del otro un átomo de nitrogeno o un eslabon -CR4-, en el que R4 representa un átomo de hidrogeno o un grupo alquilo C1-4 o alcoxi; A representa un grupo arilo o heteroarilo, estando dichos grupos arilo o heteroarilo sustituidos opcionalmente con uno o varios grupos elegidos entre un átomo de un grupo hidroxi, alquilo C1-4, cicloalquiloC3-5, alcoxi C1-4 opcionalmente con un grupo alcoxi C1-4, halogenoalquilo, halogenoalcoxi, un grupo nitrilo W representa un átomo de halogeno o un grupo halogenoalquilo; Z representa un grupo alquileno C1-4 sustituido opcionalmente con uno o varios grupos elegidos entre un átomo de halogeno y los grupos alquilo C1-4, hidroxi y alcoxi C1-4; B representa un grupo -NR4R5, en el que R4 y R5 representan independientemente el uno del otro un grupo alquilo C1-4 R1 y R2 representan: bien, R1 representa un átomo de hidrogeno y R2 representa un grupo alquilo C1-4; bien R1 y R2 forman juntos, con el átomo de carbono al que están unidos, un sistema mono o policíclico elegido entre un grupo cicloalquilo C3-8, un grupo bicíclico con enlaces puente o un grupo tetracíclico con enlaces puente, pudiendo estar dicho sistema sustituido con uno o varios grupos hidroxi; R3 representa: bien un grupo C(O)R5 con R5 que representa un grupo alcoxi C1-4 sustituido opcionalmente con un grupo alcoxi C1-4 o un grupo NR6R7 con R6 y R7 independientemente el uno del otro que representan un átomo de hidrogeno, un grupo alquilo C1-4, cicloalquilo C3-5, alquil C1-4 sulfonilo, halogenoalquilo, bien un grupo -CH2XR8 con: X que representa un átomo de oxígeno y R8 que representa un átomo de hidrogeno o un grupo alquilo C1-4, o X que representa un grupo NH y R8 que representa un grupo alquil C1-4 carbonilo, alquil C1-4 carboxilo o alquil C1-4 sulfonilo, bien un grupo nitrilo(CN) p representa un numero entero igual a 0 o 1, en el estado de base o de sal de adicion a un ácido o a una base, así como sus enantiomeros y diastereoisomeros, incluidas sus mezclas racémicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800651A FR2927330B1 (fr) | 2008-02-07 | 2008-02-07 | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070573A1 true AR070573A1 (es) | 2010-04-21 |
Family
ID=39434382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100392A AR070573A1 (es) | 2008-02-07 | 2009-02-05 | Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8466292B2 (es) |
| EP (1) | EP2238110B1 (es) |
| JP (1) | JP2011511046A (es) |
| KR (1) | KR20100116183A (es) |
| CN (1) | CN101981008B (es) |
| AR (1) | AR070573A1 (es) |
| AT (1) | ATE530527T1 (es) |
| AU (1) | AU2009227091B2 (es) |
| BR (1) | BRPI0907719A2 (es) |
| CA (1) | CA2715096A1 (es) |
| CY (1) | CY1112670T1 (es) |
| DK (1) | DK2238110T3 (es) |
| ES (1) | ES2375339T3 (es) |
| FR (1) | FR2927330B1 (es) |
| HR (1) | HRP20120069T1 (es) |
| IL (1) | IL207356A0 (es) |
| MX (1) | MX2010008713A (es) |
| PL (1) | PL2238110T3 (es) |
| PT (1) | PT2238110E (es) |
| RU (1) | RU2497808C2 (es) |
| SI (1) | SI2238110T1 (es) |
| WO (1) | WO2009115665A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2013326867B2 (en) | 2012-10-05 | 2018-03-08 | Rigel Pharmaceuticals, Inc. | GDF-8 inhibitors |
| HUE054183T2 (hu) | 2013-12-24 | 2021-08-30 | Bristol Myers Squibb Co | Triciklusos vegyület rákellenes szerekként |
| CN114712513B (zh) | 2015-02-27 | 2026-02-10 | 钙医学公司 | 胰腺炎治疗 |
| EP3294736B1 (en) | 2015-05-11 | 2020-07-22 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
| AU2016306301B2 (en) * | 2015-08-07 | 2021-02-11 | Calcimedica, Inc. | Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury |
| EP3341372A1 (en) | 2015-08-25 | 2018-07-04 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| RU2745707C2 (ru) | 2015-11-23 | 2021-03-30 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| CA3016187A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| US12544371B2 (en) | 2020-03-20 | 2026-02-10 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| CN117504933A (zh) * | 2022-07-26 | 2024-02-06 | 中国科学院上海有机化学研究所 | 羟基取代的吡啶-2-羧酸酰胺配体及其在铜催化芳基卤代物偶联反应中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0104332D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| CA2515780C (en) * | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| WO2004078114A2 (en) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| FR2856684B1 (fr) * | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
| FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
-
2008
- 2008-02-07 FR FR0800651A patent/FR2927330B1/fr not_active Expired - Fee Related
-
2009
- 2009-02-05 AU AU2009227091A patent/AU2009227091B2/en not_active Ceased
- 2009-02-05 PT PT09721603T patent/PT2238110E/pt unknown
- 2009-02-05 CA CA2715096A patent/CA2715096A1/fr not_active Abandoned
- 2009-02-05 HR HR20120069T patent/HRP20120069T1/hr unknown
- 2009-02-05 AT AT09721603T patent/ATE530527T1/de active
- 2009-02-05 AR ARP090100392A patent/AR070573A1/es not_active Application Discontinuation
- 2009-02-05 SI SI200930139T patent/SI2238110T1/sl unknown
- 2009-02-05 RU RU2010137115/04A patent/RU2497808C2/ru not_active IP Right Cessation
- 2009-02-05 DK DK09721603.0T patent/DK2238110T3/da active
- 2009-02-05 EP EP09721603A patent/EP2238110B1/fr active Active
- 2009-02-05 ES ES09721603T patent/ES2375339T3/es active Active
- 2009-02-05 KR KR1020107017495A patent/KR20100116183A/ko not_active Withdrawn
- 2009-02-05 JP JP2010545523A patent/JP2011511046A/ja active Pending
- 2009-02-05 WO PCT/FR2009/000128 patent/WO2009115665A1/fr not_active Ceased
- 2009-02-05 BR BRPI0907719-7A patent/BRPI0907719A2/pt not_active IP Right Cessation
- 2009-02-05 PL PL09721603T patent/PL2238110T3/pl unknown
- 2009-02-05 MX MX2010008713A patent/MX2010008713A/es active IP Right Grant
- 2009-02-05 CN CN2009801112181A patent/CN101981008B/zh not_active Expired - Fee Related
-
2010
- 2010-08-02 IL IL207356A patent/IL207356A0/en unknown
- 2010-08-06 US US12/851,941 patent/US8466292B2/en not_active Expired - Fee Related
-
2012
- 2012-01-25 CY CY20121100089T patent/CY1112670T1/el unknown
-
2013
- 2013-05-15 US US13/894,872 patent/US8653276B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0907719A2 (pt) | 2015-07-14 |
| SI2238110T1 (sl) | 2012-02-29 |
| ES2375339T3 (es) | 2012-02-29 |
| AU2009227091A1 (en) | 2009-09-24 |
| FR2927330B1 (fr) | 2010-02-19 |
| JP2011511046A (ja) | 2011-04-07 |
| RU2010137115A (ru) | 2012-03-20 |
| EP2238110A1 (fr) | 2010-10-13 |
| AU2009227091B2 (en) | 2013-05-23 |
| RU2497808C2 (ru) | 2013-11-10 |
| DK2238110T3 (da) | 2012-02-20 |
| US20130252974A1 (en) | 2013-09-26 |
| US8466292B2 (en) | 2013-06-18 |
| ATE530527T1 (de) | 2011-11-15 |
| CN101981008A (zh) | 2011-02-23 |
| KR20100116183A (ko) | 2010-10-29 |
| US8653276B2 (en) | 2014-02-18 |
| PL2238110T3 (pl) | 2012-03-30 |
| HRP20120069T1 (hr) | 2012-02-29 |
| WO2009115665A1 (fr) | 2009-09-24 |
| FR2927330A1 (fr) | 2009-08-14 |
| US20110009426A1 (en) | 2011-01-13 |
| CN101981008B (zh) | 2013-07-31 |
| CA2715096A1 (fr) | 2009-09-24 |
| CY1112670T1 (el) | 2016-02-10 |
| IL207356A0 (en) | 2010-12-30 |
| MX2010008713A (es) | 2010-09-09 |
| EP2238110B1 (fr) | 2011-10-26 |
| PT2238110E (pt) | 2012-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000127A1 (es) | Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| ECSP088871A (es) | Derivados de triazolopirazina | |
| CY1118973T1 (el) | Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων | |
| BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
| ECSP11011561A (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| AR060429A1 (es) | Compuestos de tioxantina y composicion farmaceutica en base a dichos compuestos | |
| UY30183A1 (es) | Derivados de quinolina | |
| ECSP12011838A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| UY29469A1 (es) | Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos. | |
| ECSP088963A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| CR9722A (es) | Derivados de benzilpiperazina y su uso medico | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |